DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for qualitative platelet defect — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleQualitative platelet defect maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for qualitative platelet defect is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ATP binding cassette subfamily C member 4 (PEL blood group) (ABCC4) — ABCC4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{s},2~{s},4~{s},5'~{r},6~{r},7~{s},8~{r},9~{s},12~{s},13~{r},16~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8XOK · 2.84 Å · ligand 2-[2-[(1~{S},2~{S},4~{S},5'~{R},6~{R},7~{S},8~{R},9~{S},12~{S},13~{R},16~{S})-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icos-18-ene-6,2'-oxane]-16-yl]oxyethyl]propane-1,3-diol (DU0). Experimental structure, not a prediction.
What the evidence adds up to
The three abstracts provided are reviews, not original clinical trials. No drug is mentioned in any of them. The 2010 review states that severe platelet function defects are rare and require management in specialised centres with full laboratory support. The 2008 review describes inherited platelet function defects as a heterogeneous group causing bleeding from mild bruising to severe haemorrhage, and notes that while many disorders share common treatments, therapies should be individualised because efficacy varies between patients. The 2015 review discusses donor-related platelet defects that may affect the quality of platelet concentrates for transfusion, but concludes that significant work remains to understand their impact on transfusion efficacy.
No concrete numbers—survival rates, response rates, or sample sizes—are given in any of these abstracts. No drug is evaluated, and no drug is named. The abstracts contain no evidence of efficacy for any treatment, and no disappointing or contradictory results are reported because no interventional data are presented.
What is still missing is any clinical trial testing a specific drug for qualitative platelet defects, any patient stratification strategy, and any funding for such trials. The reviews call for better diagnostic methods and individualised therapy, but provide no data to guide drug repurposing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Haematology · 2010 · 98 citations · open access
Modern management of severe platelet function disorders
AbstractSevere platelet function defects are rare disorders that require expertise in diagnosis and management. Therefore patients with such disorders should be referred to and managed in centres with the full laboratory repertoire of tests and clinical support necessary to optimise their quality of care. The aim of this review is to discuss the management of these patients in various clinical situations including surgical intervention.
AbstractInherited defects of platelet function are a heterogeneous group of disorders that can result in bleeding symptoms ranging from mild bruising to severe mucocutaneous haemorrhage. These defects may be classified according to their effect on the various steps of platelet microthrombi formation including initiation, extension and cohesion, or based on their particular structural or functional deficiency. Platelet membrane receptor deficiencies result in the rare, but well-characterized syndromes of defective clot initiation, such as Bernard-Soulier Syndrome. Platelet storage pool defects are the most common disorders affecting the extension phase of clot formation. Glanzmann thrombasthenia, with absent or dysfunctional alpha IIb beta 3 receptor is the prototypical defect of the cohesion/aggregation phase of microthrombi formation. Many of these disorders share common treatments although some therapies will have greater efficacy for one patient than another and should be individualized so as to provide optimal control of symptoms. Currently much effort is being put into methods to more rapidly and accurately diagnose patients with platelet disorders and to initiate appropriate therapy and prevent life threatening bleeding.
Journal of Health Specialties · 2015 · 4 citations
Factors related to blood donors that may affect the quality of platelet concentrates
AbstractThis review is intended to summarize the literature in regard to blood donor-related platelet defects that might affect the quality of platelet concentrates (PCs). Donor-related platelet defects can be defined as all platelet defects, transient or permanent in nature, which may undermine the effectiveness of platelet therapy that are caused by factors related to the donor, and not due to collection, processing or storage. Although it seems that those factors might affect the quality of PCs, there is still significant work that needs to be done to understand their impact on the efficacy of platelet transfusion.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
